1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Real-time Estimate Cboe Europe  -  10:28 2022-08-12 am EDT
1445.90 GBX   +3.28%
10:00aBiotech stocks pin bounce back hopes on M&A boost
RE
08:53aFDA and EMA have concluded there is no evidence of a causal association between ranitidine therapy and the development of cancer
AQ
06:25aSTATEMENT : Zantac (ranitidine) litigation - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK Investor Support For Spin-Off Vindicates Rejection Of Unilever Bid, Says Chief - FT

07/06/2022 | 01:01pm EDT

July 6 (Reuters) -

* GSK INVESTOR SUPPORT FOR SPIN-OFF VINDICATES REJECTION OF UNILEVER BID, SAYS CHIEF - FT


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 3.16% 1444.4 Delayed Quote.-14.82%
UNILEVER PLC -0.79% 3891 Delayed Quote.-0.62%
All news about GSK PLC
10:00aBiotech stocks pin bounce back hopes on M&A boost
RE
08:53aFDA and EMA have concluded there is no evidence of a causal association between ranitid..
AQ
06:25aSTATEMENT : Zantac (ranitidine) litigation - Form 6-K
PU
06:06aMARKETSCREENER'S WORLD PRESS REVIEW : August 12, 2022
MS
05:42aEUROPEAN MIDDAY BRIEFING : Shares Edge Higher as Inflation Fears Ease
DJ
05:11aNORTH AMERICAN MORNING BRIEFING : Stock Futures Rise as Debate Over Inflation's Path Conti..
DJ
04:58aFTSE 100 rises after better-than-feared GDP reading
MS
04:47aEuropean shares rise as healthcare rebounds, travel stocks gain
RE
04:24aGSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
RE
03:30aLONDON STOCK EXCHANGE : FTSE 100 climbs on smaller-than-expected GDP contraction, GSK rebo..
RE
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 29 644 M 36 203 M 36 203 M
Net income 2022 4 364 M 5 329 M 5 329 M
Net Debt 2022 15 314 M 18 703 M 18 703 M
P/E ratio 2022 12,9x
Yield 2022 4,26%
Capitalization 56 676 M 69 216 M 69 216 M
EV / Sales 2022 2,43x
EV / Sales 2023 2,25x
Nbr of Employees 90 096
Free-Float 93,6%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 400,00 GBX
Average target price 2 038,46 GBX
Spread / Average Target 45,6%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-14.82%69 216
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-18.19%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211